Vir Biotechnology, Inc. — Director's Dealing 2019

Oct 16, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2019-10-16

Reporting Person: Alaska Permanent Fund Corp (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-10-16	Common Stock	C	2222222	—	Acquired	5555556	Indirect
2019-10-16	Common Stock	C	666667	—	Acquired	5555556	Indirect
2019-10-16	Common Stock	C	1111111	—	Acquired	5555556	Indirect
2019-10-16	Common Stock	C	55556	—	Acquired	5555556	Indirect
2019-10-16	Common Stock	P	1500000	$20	Acquired	5555556	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-10-16	Series A-1 convertible preferred stock	$	C	2222222	Disposed		Common Stock (2222222)	Indirect
2019-10-16	Series A-1 convertible preferred stock	$	C	666667	Disposed		Common Stock (666667)	Indirect
2019-01-16	Series B convertible preferred stock	$	C	1111111	Disposed		Common Stock (1111111)	Indirect
2019-10-16	Series B convertible preferred stock	$	C	55556	Disposed		Common Stock (55556)	Indirect

Footnotes

F1: Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above.